News and Announcements
Nico.lab Fundraising Ahead of IPO for Stroke Treatment Technology
- Published June 12, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Nico.lab’s technology enables the fast and accurate image analysis to allow for quick decisions to be made by Doctors.
- The company is planning to raise funds before their IPO in February 2019.
- The funds they plan on raising will help accelerate the strategy to bring their technology, StrokeViewer, to the market in Australia and Europe.
Nico.lab, established in 2015, is planning to raise funds before their IPO in February 2019. The funds they plan on raising will help accelerate the strategy to bring their technology, StrokeViewer, to the market in Australia and Europe. Their technology aims to reduce the treatment time for stroke patients. It will also fund the development of the AI algorithm required for effective stroke detection over the next 12 months. The IPO Funds in February 2019 will focus on the technology rollout in the United States.
Nico.lab’s technology enables the fast and accurate image analysis to allow for quick decisions to be made by Doctors. It will reduce treatment time from hours to minutes. The technology has all four biomarkers required for accurate stroke detection. Within 3 minutes the StrokeViewer informs doctors with a biomarker report and image they can view on any device. Every hour that doctors can treat a stroke victim, the number of patients who recover without significant complications increase by 15%.
The CE certified technology uses artificial intelligence and machine learning to improve performance continually. Nico.lab has had 15 hospitals in the Netherlands sign up to use the technology. Peak Asset Management, an advisory firm, is planning to raise $2.3m, with the shares priced at 15¢, for Nico.lab before the IPO next year.
About Nico.Lab
Nico.lab’s StrokeViewer® uses AI to reduces time-to-decision for stroke patients to 3 minutes compared to the current manual protocol which can take hours.
StrokeViewer® has been approved for roll-out by 15 hospitals.
The company has an exceptional management team and board, with over €4M and years of research spent to date.
Investors have an opportunity at a compelling €4.5M pre-money valuation, ahead of an ASX listing in 1Q18.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
